Astrazenca reveals positive results from Phase III trial of Lynparza
Category: #health  By Pankaj Singh  Date: 2019-08-09
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Astrazenca reveals positive results from Phase III trial of Lynparza

Lynparza is a PARP inhibitor with promising Phase III results in ovarian breast pancreatic and prostate cancers.

AstraZeneca plc a biopharmaceutical company and MSD Inc. (also known as Merck & Co. Inc. inside Canada and the U.S.) have recently announced positive results from the Phase III PROfound trial of Lynparza in men who suffer from metastatic castration-resistant prostate cancer (mCRPC) with a HRRm (homologous recombination repair gene mutation) and have progressed with prior treatment with new hormonal anticancer therapeutics like abiraterone and enzalutamide.

According to reliable reports the trial’s outcome showed a clinically meaningful and statistically-significant development in the primary endpoint of radiographic progression-free survival (rPFS) with Lynparza vs. abiraterone or enzalutamide in men with mCRPC chosen for BRCA1/2 or ATM gene mutations, a subtype of HRR gene mutations. The tolerability and safety profile of Lynparza was also normally steady with previous trials.

Speaking on the move, Jose Baselga Executive Vice President, Oncology R&D, said that for men suffering from metastatic castration-resistant prostate cancer the disease is still deadly mainly for ones who have failed on a new hormonal anticancer treatment.

He added; the PROfound trial shows the promising value of genomic testing in at-risk patient population and the company is looking forward to discussing these results with international health authorities soon.

Roy Baynes, Chief Medical Officer, MSD Research Laboratories, and Head and Senior Vice President of Global Clinical Development said that Metastatic castration-resistant prostate cancer remains a fatal disease and an area of extensive needed medical attention. He claims that the PROfound Phase III trial is an example of AstraZeneca and MSD’s shared promise to develop long-term results for people suffering from cancer.

As per reports, AstraZeneca and MSD are planning to reveal the full data from their trial at an upcoming medical meeting. Currently the organizations are seeking other trials in prostate cancer, which includes the Phase III PROpel trial and piloting Lynparza as a first-line therapy in mCRPC in combined with abiraterone.

Source Credit: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2019/lynparza-phase-iii-profound-trial-in-hrr-mutation-selected-metastatic-castration-resistant-prostate-cancer-met-primary-endpoint-07082019.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

PCS Software adds new contactless features to expand TMS platform

PCS Software adds new contactless features to expand TMS platform

By Pankaj Singh

  • With this addition, it is now possible for PCS consumers to effectively manage their workflows using their mobile devices
  • Document digitization has...

ODP teams up with Microsoft to support shared & new B2B customers

ODP teams up with Microsoft to support shared & new B2B customers

By Pankaj Singh

The ODP Corporation, an American retail company, has recently announced the expansion of its long-standing relationship with Microsoft. The two companies are planning to boost efficiencies and growth of their shared as...

Gannex reveals positive data from ASC41 clinical study in 20 subjects

Gannex reveals positive data from ASC41 clinical study in 20 subjects

By Pankaj Singh

Ascletis Pharma Inc.’s wholly-owned company, Gannex, has reportedly announced the positive clinical data from its ASC41 trial conducted among overweight and obese subjects. The active metabolite of this liver-tar...